Bioequivalence comparison between hydroxyethyl starch 130/0.42/6: 1 and hydroxyethyl starch 130/0.4/9: 1

Drugs in R and D

Volumn 8, Issue 4, 2007, Pages 229-240

  Lehmann, G ^a   Marx, G ^b   Forster H ^c  

^a Rhoen Hospital Bad Berka   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HETASTARCH; UNCLASSIFIED DRUG; VENOFUNDIN;

ADULT; ANALYTIC METHOD; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG CLEARANCE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRY SKIN; FEMALE; HEMODILUTION; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; ONCOTIC PRESSURE; PLASMA VISCOSITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SWEATING;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; BLOOD VISCOSITY; CREATININE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HALF-LIFE; HEADACHE; HEMATOCRIT; HEMOGLOBINS; HETASTARCH; HUMANS; INFUSIONS, INTRAVENOUS; MALE; OSMOTIC PRESSURE; PLASMA SUBSTITUTES; SOLUTIONS; THERAPEUTIC EQUIVALENCY; TIME FACTORS;

EID: 34347369785     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200708040-00003     Document Type: Article

References (25)

1. Weidler B, Sommermeyer K. Hydroxyethylstärke-Kinetik im Probandenversuch: Einfluß von Molekulargewicht, Substitution und Substitutionsposition. In: Lawin P, Zander J, Weidler B, editors. Hydroxyethylstärke. Stuttgart: Thieme, 1989: 45-55
2. Asskali F, Förster H. Zur Kumulation unterschiedlich substituierter Hydroxyethylstärke (HES) nach repetitiver Infusion bei gesunden Versuchspersonen. AINS 1999; 34: 537-41
3. Lehmann G, Asskali F, Förster H. Pharmacokinetics of hydroxyethylstarch (70/0.5) following repeated infusions. Transfus Med Hemother 2003; 30: 72-7
4. Boldt J. New light on intravascular volume replacement regimens: what did we learn from the past three years? Anesth Analg 2003; 97: 1595-604
5. Treib J, Baron JF, Grauer MT, et al. An international view of hydroxyethyl starches. Intensive Care Med 1999; 25: 258-68
6. Asskali F, Lehmann G, Förster H. Thrombelastographic coagulation analysis following in vitro and in vivo haemodilution with hydroxyethyl starch (HES). Anasthesiol Intensivmed Notfallmed Schmerzther 2002 May; 37 (5): 258-66
7. Asskali F, Lehmann G, Förster H. Pharmakokinetik und Pharmakodynamik von zwei HES-Lösungen auf Basis unterschiedlicher Rohstoffe: Eine Bioäquivalenzprüfung. Krankenhauspharmazie 2000; 7: 362-8
8. Richterich R, Colombo JP. Klinische Chemie, 3rd ed. Basel: Karger, 1971, 261f
9. Förster H, Wikarkzyk C, Dudziak R. Bestimmung der Plasmaelimination von Hydroxyethylstärke und Dextran mittels verbesserter analytischer Methodik. Infusionstherapie 1981; 8: 88-94
10. Schuirman DJ. A comparison of two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80
11. Waitzinger J, Bepperling F, Pabst G, et al. Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification [HES (130/0.4)] after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Invest 1998; 16: 151-60
12. N.N. Scientific information Voluven. Fresenius Kabi Deutschland GmbH, Bad Homburg, Germany, 2002
13. Ferber HP, Nitsch E, Förster H. Studies on hydroxyethyl starch: part II. Changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/0.7, 200/0.5, 200/0.3 and 200/0.1 after infusion in serum and urine of volunteers. Arzneimittelforschung 1985; 35: 615-22
14. Förster H. Physical and chemical properties of hydroxyethyl starches. In: Baron JF, editor. Plasma volume expansion. Paris: Arnette, 1992, 120
15. Yoshida M, Yamashita T, Matsuo J, et al. Enzymic degradation of hydroxyethyl starch: Part I. Influence of the distribution of hydroxyethyl groups on the enzymic degradation of hydroxyethyl starch. Stärke 1973; 25: 373
16. Yoshida M, Muiami Y, Kishikawa T. A study of hydroxyethyl-starch: Part III. Comparison of metabolic fates between 2-O-hydroxyethyl starch and 6-O-hydroxyethyl starch in rabbits. Staerke 1984; 36: 209-12
17. Jung F, Koscielny J, Mrowietz C, et al. The effect of molecular structure of hydroxyethyl starch on the elimination kinetics and fluidity of blood in human volunteers. Arzneimittelforschung 1993; 43: 99-105
18. Treib J, Haass A, Pindur G, et al. HES 200/0.5 is not HES 200/0.5: influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 1995; 74: 1452-6
19. Orth VH, Rehm M, Haller M, et al. The measurement of blood volume: state-of-the-art. Anaesthesist 2001 Aug; 50 (8): 562-8
20. Sander O, Reinhart K, Meier-Hellmann A. Equivalence of hydroxyethyl starch HES 130/0.4 and HES 200/0.5 for perioperative volume replacement in major gynaecological surgery. Acta Anaesthesiol Scand 2003; 47: 1151-8
21. Langeron O, Doelberg M, Ang ET, et al. Voluven®, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001; 92: 855-62
22. Gallandat Huet RCG, Siemons AW, Baus D, et al. A novel hydroxyethyl starch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anesth 2000; 47: 1207-15
23. James MFM, Latoo MY, Mythen MG, et al. Plasma volume changes associated with two hydroxyethyl starch colloids following acute hypovolaemia in volunteers. Anaesthesia 2004; 59: 738-42
24. Altman C, Bernard B, Roulot D, et al. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. Eur J Gastroenterol Hepatol 1998; 10: 5-10
25. Mimoz O, Soreda S, Padoin C, et al. Ceftriaxone pharmacokinetics during iatrogenic hydroxyethyl starch induced hypoalbuminemia: a model to explore the effects of decreased protein binding capacity on highly bound drugs. Anesthesiology 2000; 93: 735-43